We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Rapid Metagenomics Diagnoses Antibiotic Resistant Bloodstream Infections 18-42 Hours Faster Than Conventional Tests

By LabMedica International staff writers
Posted on 20 Apr 2023
Print article
Image: Metagenomic sequencing outperforms conventional tests to identify AMR in bloodstream infections (Photo courtesy of Freepik)
Image: Metagenomic sequencing outperforms conventional tests to identify AMR in bloodstream infections (Photo courtesy of Freepik)

Bloodstream infections can quickly progress to sepsis, multiple organ failure, and even death. Timely and appropriate antibiotic therapy is crucial for managing the infection. Antimicrobial resistance (AMR) poses a significant challenge in treating bloodstream infections. Current clinical methods for identifying the causative pathogen are lengthy and labor-intensive, involving two culture and sensitivity tests that take at least 1 to 3 days to complete—first isolating and identifying the pathogen and then performing antimicrobial susceptibility testing. Now, new research presented at ECCMID 2023 demonstrates that metagenomic sequencing can offer rapid and actionable AMR predictions for treating bloodstream infections much faster than traditional laboratory tests, potentially saving lives and improving antibiotic management.

The study conducted by researchers at the University of Oxford (Oxford, UK) reveals that rapid metagenomics can provide accurate results within just six hours of detecting bacterial growth in a blood sample. Clinical metagenomics sequences all genetic material, including infectious pathogens, in a sample simultaneously, reducing the time spent on running tests, waiting for results, and conducting additional tests. For their study, the Oxford researchers randomly selected 210 positive and 61 negative blood culture specimens for metagenomic sequencing, using the Oxford Nanopore GridION platform to sequence DNA. The sequences were utilized to identify the pathogen species causing infections and to detect common species that can contaminate blood cultures.

Sequencing successfully identified 99% of infecting pathogens, including polymicrobial infections and contaminants, and yielded negative results in 100% of culture-negative samples. In some cases, sequencing detected probable infection causes that routine cultures missed, while in others, it identified uncultivable species when a result could not be determined. Sequencing could also detect antibiotic resistance in the 10 most common infection causes. A total of 741 resistant and 4047 sensitive antibiotic-pathogen combinations were examined, with traditional culture-based testing and sequencing results agreeing 92% of the time. Comparable performance could be achieved using raw reads after just two hours of sequencing, with an overall agreement of 90%. The average time from sample extraction to sequencing was four hours, with complete AMR prediction achieved two hours later, providing actionable AMR results 18-42 hours sooner than conventional laboratory methods.

“Antibiotic resistant bloodstream infections are a leading killer in hospitals, and rapidly starting the right antibiotic saves lives,” said Dr. Kumeren Govender from the John Radcliffe Hospital, University of Oxford, who led the study. “Our results suggests that metagenomics is a powerful tool for the rapid and accurate diagnosis of pathogenic organisms and antimicrobial resistance, allowing for effective treatment 18 to 42 hours earlier than would be possible using standard culture techniques.”

“This is a really exciting breakthrough that means we will be able to diagnose the cause of patients’ infections faster and more completely than has been possible before,” added David Eyre, Professor of Infectious Diseases at the University of Oxford, who co-led the study. “We are working hard to continue to overcome some of the remaining barriers to metagenomic sequencing being used more widely, which include its current high cost, further improving accuracy, and creating improved laboratory expertise in these new technologies and simpler workflows for interpreting results.”

Related Links:
University of Oxford 

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
POCT Fluorescent Immunoassay Analyzer
C. difficile Toxins Test

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)

Blood Tests to Enable Early Identification of Cognitive Decline and Personalized Treatments

Some individuals who have endured extreme stressors like psychiatric disorders or childhood abuse and neglect can experience a variety of health issues later in life, such as depression, anxiety, and cardiovascular... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.